Business Featured Gujarat National

Emergency use of Zydus Cadila’s Pegylated Interferon alpha-2b gets DCGI’s approval

(G.N.S) Dt. 23

New Delhi

Emergency use for Zydus Cadila’s Pegylated Interferon alpha-2b has got an approval from Drugs Controller General of India (DCGI).

Virafin’ for the treatment of moderate Covid-19 infection in adults.

In a statement, the company informed, “PegIFN in COVID-19 has several add-on advantages compared to other anti-viral agents. The treatment regimen would be less cumbersome and more affordable for patients as Pegylated Interferon Alpha 2b, is a single dose regimen. It would also ensure better compliance. PegIFN has very well-established safety with multiple doses in chronic hepatitis B and C patients since many years. Patients on Pegylated Interferon Alpha 2b during the trial also showed lesser need for supplemental oxygen, clearly indicating that it was able to control respiratory distress and failure which has been one of the major challenges in treating COVID-19. The findings are in line with recently reported importance of early IFN treatment given in combination with steroids in the treatment of COVID-19 (Lu et al, Signal Transduction and Targeted Therapy (2021) 6:107, a Nature publication.”

Related posts

J&K authorities sent 168 Rohingyas to jail after they were found staying illegally


The Biggest Mistakes Influencers Make on Instagram


CJI Bobde recommends SC’s senior most judge Justice N V Ramana, as his successor


Leave a Comment